New and experimental hepatitis C treatment

New and experimental hepatitis C treatment features

• 

  We’re getting there: towards a comprehensive hepatitis C cure

  Research on new cures for hepatitis C has made rapid progress, Gus Cairns reports....

  From:HIV treatment update

• 

  Combinations and conundrums: the challenges of hepatitis C treatment

  A multiplicity of new drugs for hepatitis C are being researched. As Gus Cairns discovers, though, they face an elusive enemy, a shape-shifter of a virus that won’t...

  From:HIV treatment update

New and experimental hepatitis C treatment news from aidsmap

• BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis

  An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C patients, with favourable safety and efficacy ...

  15 May 2012 | Liz Highleyman

• Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir

  Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th International Liver Congress (EASL 2012) in ...

  11 May 2012 | Liz Highleyman

• Promising findings for therapeutic hepatitis C vaccine TG4040

  An investigational hepatitis C virus (HCV) therapeutic vaccine significantly improved the likelihood of sustained response to interferon-based therapy, according to a proof-of-concept study reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona. Interferon-based therapy and new direct-acting antiviral ...

  09 May 2012 | Liz Highleyman

• GS-7977 with interferon/ribavirin cures most treatment-naive hepatitis C patients in 12 weeks

  Adding GS-7977 to pegylated interferon and ribavirin for 12 weeks led to a sustained response rate of 90% for previously untreated chronic hepatitis C patients with difficult-to-treat genotype 1, researchers reported at the 47th International Liver Congress (EASL 2012) last ...

  30 April 2012 | Liz Highleyman

• Abbott interferon-free HCV combinations show early promise in untreated patients

  Two interferon-free antiviral regimens being developed by Abbott showed high hepatitis C cure rates in small studies of treatment-naïve patients presented last week at the International Liver Congress in Barcelona. Abbott is pursuing the development of several interferon-free regimens in which ...

  23 April 2012 | Keith Alcorn

• Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy

  A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40 and 68% in patients who did not respond to a previous course of hepatitis C therapy, data presented to the 47th International Liver Congress ...

  23 April 2012 | Michael Carter

• Adding TMC435 boosts response for difficult-to-treat hepatitis C patients

  A combination of TMC435 – also known as simeprevir – plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according to a study presented at the ...

  23 April 2012 | Liz Highleyman

• Hepatitis C drug alisporivir is effective, but pancreatitis a concern

  Alisporivir (formerly Debio 025) in interferon-free combinations cured more than 80% of patients with hepatitis C virus (HCV) genotype 2 or 3, researchers reported at the 47th International Liver Congress (EASL 2012) last week in Barcelona. The drug has been ...

  23 April 2012 | Liz Highleyman

• Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment

  A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations ...

  20 April 2012 | Keith Alcorn

• Hepatitis C meds GS-7977, daclatasvir and asunaprevir look good in interferon-free combos

  Most previously untreated people with chronic hepatitis C achieved an early cure with an all-oral combination of the HCV NS5A inhibitor daclatasvir plus the polymerase inhibitor GS-7977, researchers reported on Thursday at the 47th International Liver ...

  20 April 2012 | Liz Highleyman

More news

New and experimental hepatitis C treatment news selected from other sources

• HCV patients may be able to delay therapy

  Hepatitis C patients without significant fibrosis may be able to delay triple therapy and wait for simpler, shorter, and potentially all-oral regimens that are currently under investigation, researchers said here.

  20 hours ago | MedPage Today

• How CDC's hep.-C testing advice is already benefiting drugmakers

  The CDC's proposal that all US baby boomers get a one-time test for the hepatitis C virus has already given a boost to drugmakers in the antiviral space. If the agency finalizes the draft guidance later this year, potentially impacting screening rates, current and future players stand to gain even more.

  20 hours ago | Medical Marketing and Media

• Incivek Rash Reports: What HIV/Hepatitis C-Coinfected People Need to Know

  It turns out that Incivek (telaprevir), one of the HCV protease inhibitors approved last year, is also associated with rash. About half of patients who take Incivek get a rash. It can sometimes be itchy, too. Most of the time the rash is mild or moderate.

  18 May 2012 | The Body

• Achillion's hepatitis C drug gets FDA fast track

  The U.S. Food and Drug Administration granted a fast track designation to Achillion Pharmaceuticals Inc's experimental hepatitis C drug ACH-3102, currently in an early-stage trial.

  16 May 2012 | Reuters

• New Drugs Require New Terms for HCV Virologic Response

  Direct-acting antiviral drugs have potent antiviral actions and appear to produce a more rapid virologic response, with or without interferon, than interferon-based regimens without the new drugs. More intuitive and flexible virologic measures are needed that can adapt to these advances in HCV treatment.

  09 May 2012 | Medscape (requires registration)

• Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy

  Aethlon Medical, Inc., the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the presence of Hepatitis C virus (HCV) is currently undetectable in all infected patients that have been treated with the Aethlon Hemopurifier® in combination with peginterferon+ribavirin (PR) drug therapy and monitored for at least ninety days.

  08 May 2012 | MarketWatch (press release)

• Bristol-Myers Missing Hep C Data Raises Red Flags, May Boost Gilead, Idenix

  I suspect something is wrong with Bristol-Myers' INX-189, which has since been renamed by the company as BMS-094. The red flags are popping up everywhere.

  08 May 2012 | The Street

• Gilead Sciences 1Q profit down on Pharmasset costs

  HIV drug maker Gilead Sciences Inc.'s profit dropped 32 percent in the first quarter on costs related to its purchase of hepatitis C drug developer Pharmasset Inc.

  27 April 2012 | CBS News

• US: do not mix Merck hepatitis pill with HIV drugs

  U.S. drug regulators are changing the label for Merck & Co Inc's recently approved Victrelis treatment for hepatitis C to show it should not be taken with some widely used HIV medicines.

  27 April 2012 | Reuters

• NICE publishes final guidance on two new drugs for chronic hepatitis C

  Healthcare guidance body NICE has today (25 April) issued final guidance recommending boceprevir (Victrelis, Merck Sharp & Dohme) and telaprevir (Incivo, Janssen Cilag), in combination with peginterferon alfa and ribavirin, as options for the treatment of genotype 1 chronic hepatitis C in adults with compensated liver disease.

  25 April 2012 | NICE press release

More news